Your session is about to expire
← Back to Search
Pregabalin vs. Gabapentin for Pain Management
Phase 4
Recruiting
Research Sponsored by CAMC Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
18 years of age or older
Active order(s) for opioids in place at the time of enrollment
Must not have
CrCl<30ml/min or on HD
History of epilepsy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up first 7 days post-enrolment or until discharge, if discharge < 7 days post-enrollment
Awards & highlights
All Individual Drugs Already Approved
Approved for 10 Other Conditions
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial
Summary
This trialtests different meds to reduce opioid use in people with orthopedic trauma.
Who is the study for?
This trial is for adults over 18 who have been admitted to a Nurse Practitioner service with single-system orthopedic trauma, need opioids, and will stay in the hospital for more than a day. It's not for those with brain injuries, complex wounds, severe kidney issues, trouble swallowing pills, intubation, epilepsy history or substance use disorder.
What is being tested?
The study compares Pregabalin (50mg) and Gabapentin (300mg) to see if they can help reduce opioid usage when given alongside standard painkillers after orthopedic trauma. Patients are randomly assigned to one of these drugs or no drug at all.
What are the potential side effects?
Possible side effects from Pregabalin and Gabapentin may include dizziness, sleepiness, swelling of hands/feet or blurred vision. They might also cause difficulty concentrating which could affect the ability to perform tasks.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I am currently prescribed opioids.
Select...
I expect to stay in the hospital for more than a day after giving consent.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My kidney function is very low or I am on dialysis.
Select...
I have a history of epilepsy.
Select...
I cannot take medications by mouth.
Select...
I have an epidural.
Select...
I am taking pregabalin or gabapentin.
Select...
I have had issues with wound healing after surgery.
Select...
I take pregabalin or gabapentin as part of my daily medications.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ first 7 days post-enrolment or until discharge, if discharge < 7 days post-enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~first 7 days post-enrolment or until discharge, if discharge < 7 days post-enrollment
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Reduction in opioid usage
Secondary study objectives
Hospital length of stay
Incentive spirometry values
Pain control
+2 moreAwards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: PregabalinExperimental Treatment1 Intervention
Group II: GabapentinExperimental Treatment1 Intervention
Group III: Neither Pregabalin nor GabapentinActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gabapentin
FDA approved
Pregabalin
FDA approved
Find a Location
Who is running the clinical trial?
CAMC Health SystemLead Sponsor
45 Previous Clinical Trials
7,786 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My kidney function is very low or I am on dialysis.I have a history of epilepsy.I cannot take medications by mouth.You are currently on a breathing machine.I have an epidural.You have experienced a head injury.I am 18 years old or older.I am currently prescribed opioids.I expect to stay in the hospital for more than a day after giving consent.I was admitted to the hospital less than 36 hours ago.I am taking pregabalin or gabapentin.I have had issues with wound healing after surgery.I take pregabalin or gabapentin as part of my daily medications.The doctor will decide if you can participate based on your medical needs.You have a record of addiction to drugs or alcohol.
Research Study Groups:
This trial has the following groups:- Group 1: Pregabalin
- Group 2: Gabapentin
- Group 3: Neither Pregabalin nor Gabapentin
Awards:
This trial has 5 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger